New drug EDI048 takes on stomach bug in human trial
NCT ID NCT07249463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called EDI048 for cryptosporidiosis, a diarrheal disease caused by a parasite. Healthy adults will be deliberately infected with the parasite and then given either EDI048 or a placebo to see if the drug reduces diarrhea severity. The goal is to gather evidence that could lead to a treatment for children, who are most affected by this infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EDI048 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment for cryptosporidiosis, especially for children who currently lack effective options.
What could go wrong
This is an early Phase 2 trial in only 96 healthy adults, not patients. The drug may not work as well in real-world settings or in children, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYPTOSPORIDIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Pharmaron Inc
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact